Economic burden of metastatic bone disease in the U.S.
Top Cited Papers
Open Access
- 18 May 2007
- Vol. 109 (11), 2334-2342
- https://doi.org/10.1002/cncr.22678
Abstract
BACKGROUND Previous research has documented the prevalence of primary bone cancer; however, there are few data available regarding the impact of metastatic bone disease (MBD) on national expenditure. In this study, the authors quantified the prevalence and direct medical care costs of patients with MBD and the resulting cost impact on U.S. oncology expenditure. METHODS Anonymous, patient-level data on health care utilization and cost were obtained from the Thomson Medstat MarketScan research databases. In total, 396,200 patients who were diagnosed with cancer between 2000 and 2004 were selected for the study. Patients with MBD were matched subsequently to non-MBD controls. A 2-part linear regression model was used to compare cases with controls to quantify the incremental cost associated with the disease. RESULTS Cancer prevalence in the U.S. during the study period was estimated at 4,861,987 cases annually, and 5.3% (n = 256,137) of those patients had MBD. Rates of MBD were highest in patients with multiple myeloma (28.8%) and lung cancer (15.6%). The mean direct medical cost for all cancers combined was $75,329 for patients with MBD and $31,382 for controls. Regression-adjusted, incremental costs were $44,442 (P < .001) across all cancer types. The incremental cost was highest for patients with multiple myeloma ($63,455) and lowest for patients with lung cancer ($24,946). CONCLUSIONS The national cost burden for patients with MBD was estimated at $12.6 billion, which is 17% of the $74 billion in total direct medical cost estimated by the National Institutes of Health, suggesting that MBD is a significant driver of overall oncology cost. Cancer 2007. © 2007 American Cancer Society.Keywords
This publication has 28 references indexed in Scilit:
- Economic burden associated with breast cancer recurrenceCancer, 2006
- The economic burden of lung cancer and the associated costs of treatment failure in the United StatesLung Cancer, 2005
- Targeting of therapeutic agents to bone to treat metastatic cancerAdvanced Drug Delivery Reviews, 2005
- The Cost of Treatment of Skeletal-Related Events in Patients with Bone Metastases from Lung CancerOncology, 2004
- Cost of Illness Associated with Metastatic Breast CancerBreast Cancer Research and Treatment, 2004
- Bone painPublished by Cambridge University Press (CUP) ,2003
- Estimates of the Lifetime Direct Costs of Treatment for Metastatic Breast CancerValue in Health, 2000
- Medicare Payments from Diagnosis to Death for Elderly Cancer Patients by Stage at DiagnosisMedical Care, 1995
- A chronic disease score from automated pharmacy dataJournal of Clinical Epidemiology, 1992
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987